Abbott Laboratories (NYSE: ABT - option chain) shares are higher today despite the surrounding market meltdown after a study released over the weekend showed the company's Xience stent showed significant safety advantages over competitor Boston Scientific's (NYSE: BSX) Taxus stent. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT.ABT opened this morning at $46.69. So far today the stock has hit a low of $46.65 and a high of $47.90. As of 11:35, ABT is trading at $47.73, up $1.13 (2.4%). The chart for ABT looks bullish and S&P gives ABT a positive 5 STARS (out of 5) strong buy ranking.
ABT hasn't been below $44 at all in the past year and has shown support around $46 recently.
Brent Archer is an options analyst and writer at Investors Observer. At publication time, Brent controls bullish hedged positions in ABT.











Reader Comments (Page 1 of 1)
6-18-2009 @ 8:41PM
angioplasty said...
I've always had luck with Roche. They are local for me and I can keep an eye on progress.
angioplasty